Feb 6, 2012 | Seeking Alpha
4 Biotech Stocks To Buy, 1 To Avoid For Now
The biotech sector has always been risky due to the fact that its product pipeline is affected by FDA approval and risks in the development of products.
CardioDx fills CFO, chief medical officer posts
Andrew Guggenhime , who was CFO of Facet Biotech Corp. and PDL BioPharma Inc. in Redwood City, joined CardioDx in the same position, the company said Monday.
Venture firms traditionally have seen big pharmaceutical companies as the most likely buyers for their biotechnology start-ups, but lately they've been selling more of them to pharma's smaller biotech rivals.
Gilead to buy Calistoga for $375M
Glead Sciences Inc. has agreed to acquire Calistoga Pharmaceuticals Inc. for $375 million, the companies said Tuesday.